Curis, Inc. Share Price Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Sales 2024 * | 8.16M 650M | Sales 2025 * | 8.76M 698M | Capitalization | 92.66M 7.38B |
---|---|---|---|---|---|
Net income 2024 * | -47M -3.74B | Net income 2025 * | -53M -4.22B | EV / Sales 2024 * | 11.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 10.6 x |
P/E ratio 2024 * |
-2.53
x | P/E ratio 2025 * |
-3.22
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Curis, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 25/07/22 |
Chief Tech/Sci/R&D Officer | - | 02/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 31/10/03 |
Martyn Greenacre
CHM | Chairman | 82 | 13/02/00 |
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |